Johnson & Johnson’s nipocalimab meets primary endpoint in Sjögren’s disease trial

Johnson & Johnson (NYSE: JNJ), a global leader in healthcare, announced significant progress in the treatment of Sjögren's disease (SjD) with its drug, nipocalimab. In ... Read More